Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

20. Februar 2020

Welt, A., Welslau, M., Lüftner, D., Deryal, M., Liersch, R., Sahlmann, J., Houet, L., Potthoff, K., Marschner, N., 2020.

Oncol Res Treat 43 (suppl 1)(270), 13–14.